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Infantile hemangioma is a vascular tumor that exhibits a unique natural cycle of rapid growth followed by involution. Previously,
we have shown that hemangiomas arise from CD133þ stem cells that differentiate into endothelial cells when implanted in
immunodeﬁcient mice. The same clonally expanded stem cells also produced adipocytes, thus recapitulating the involuting
phase of hemangioma. In the present study, we have elucidated the intrinsic mechanisms of adipocyte differentiation using
hemangioma-derived stem cells (hemSCs). We found that platelet-derived growth factor (PDGF) is elevated during the
proliferating phase and may inhibit adipocyte differentiation. hemSCs expressed high levels of PDGF-B and showed sustained
tyrosine phosphorylation of PDGF receptors under basal (unstimulated) conditions. Inhibition of PDGF receptor signaling
caused enhanced adipogenesis in hemSCs. Furthermore, exposure of hemSCs to exogenous PDGF-BB reduced the fat content
and the expression of adipocyte-speciﬁc transcription factors. We also show that these autogenous inhibitory effects are
mediated by PDGF receptor-b signaling. In summary, this study identiﬁes PDGF signaling as an intrinsic negative regulator of
hemangioma involution and highlights the therapeutic potential of disrupting PDGF signaling for the treatment of hemangiomas.
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Infantile hemangioma is the most common tumor of infancy.
1
This vascular lesion appears in 4–10% of newborns, and is
especially prevalent in Caucasian infants.
1,2 Occasionally,
hemangiomas cause signiﬁcant morbidity through obstruc-
tion, ulceration, or compromised cardiovascular function.
1,3
Therefore, optimal clinical management of hemangiomas is
still an active area of research.
3 Hemangioma pathogenesis
involves a predictable pattern of growth. During the ﬁrst few
months of the infant’s life, the tumor proliferates rapidly and
reaches a maximum size.
4 Then spontaneous involution over
the ﬁrst several years of childhood ensues. By adolescence,
involution is complete, and the tumor is a ﬁbrofatty mass
bearing little resemblance to the highly vascular original.
3
From a research perspective, hemangioma provides a unique
model system for studying blood vessel growth and regula-
tion and the interaction between the blood vessels and
adipogenesis.
Until recently, the molecular mechanisms underlying
hemangioma growth and involution have been poorly under-
stood. Recent studies have probed the genetic and biochem-
ical basis for the appearance and regression of this vascular
tumor. In a study of familial hemangiomas, genetic linkage
analysis identiﬁed platelet-derived growth factor receptor b
(PDGFR-b) as a possible contributor to hemangioma
heredity.
5 Later, a study examining global gene expression
changes between the hemangioma growth phases by micro-
array proﬁling showed a reduction in PDGFR-b expression
during the involutive phase.
6 Although the levels of PDGFRs
are lower than placenta (a commonly used tissue for
comparisons), the ﬁndings do point to a possible role for
PDGF signaling in hemangioma pathogenesis.
The PDGF family of growth factors is comprised of several
disulﬁde-bound dimers that bind tyrosine kinase receptors.
7
PDGF ligands include PDGF-AA, -AB, -BB, -CC, and -DD (all
comprising two joined peptide chains of A, B, C, or D; PDGF-
AB is the only heterodimer reported) and exert their effects by
binding to one or both of two structurally related receptors,
PDGFR-a and PDGFR-b. The two receptors show over-
lapping but non-identical signaling functions. PDGFR-a binds
to all PDGF chains except for PDGF-D and PDGFR-b binds
only to the PDGF-B and PDGF-D chains. However, further
complexity and/or ﬁne-tuning can be achieved by receptor
hetero-dimerization. PDGFR-ab heterodimers may bind to
PDGF-B, -C, and -D homodimers as well as the PDGF-AB
heterodimer. Upon activation, a diverse range of cellular
activities is altered, including cell survival and proliferation,
chemotaxis, and angiogenesis.
7 Not surprisingly, aberrant
PDGF signaling has been implicated in a variety of
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7,8
The purpose of this study was to investigate the role of
PDGF signaling in the involution of infantile hemangioma. As
PDGF signaling has a positive effect on the formation of
vascular networks,
9,10 we hypothesize that PDGF growth
factors are negative regulators of hemangioma involution. We
investigated the presence of PDGF ligands and receptors in
hemangioma specimens and hemangoma-derived cells. We
then tested the effects of PDGF ligands on the adipogenic
differentiation of hemangioma cells and identiﬁed the
receptor.
Results
Decrease in PDGFR expression coincides with heman-
gioma involution. Our ﬁrst objective was to determine
whether hemangioma specimens express PDGFRs. To
achieve this, we obtained proliferating hemangioma speci-
mens and normal human skin tissues for comparisons.
Our results show signiﬁcantly elevated PDGFR-a and
PDGFR-b in proliferating hemangiomas as compared with
normal skin (Figure 1a). The involutive phase of heman-
gioma was associated with increased PPARg expression
(transcription factor involved in adipogenesis) and reduced
levels of both PDGFRs. We next determined the localization
of the PDGFRs in proliferating hemangiomas. Immunohis-
tochemistry showed predominant PDGFR-a localization to
the endothelial cells (Figure 1b). PDGFR-b, on the other
hand, showed more widespread distribution, being localized
to the vascular endothelial and perivascular cells, and the
stroma/interstitial cells. This distribution pattern of PDGFR-b
was conﬁrmed by double-labeling with PDGFR-b antibody
and alpha-smooth muscle actin (a-SMA) (mural cell marker)
antibody (Figure 1c).
We next determined the activity of the PDGFRs in
hemangioma specimens using phospho-speciﬁc PDGFR
antibodies. Immunoﬂuorescence staining showed that both
PDGFR-a and PDGFR-b are phosphorylated at tyrosine 849
and1021,respectively(Figure2).Thesephosphorylatedsites
inthePDGFRsarecommonlyusedtodeterminetheactivated
form of the receptors.
Figure 1 Expression of PDGF receptors in proliferating and involuting hemangiomas. (a) Real-time RT-PCR analysis of PDGFR-a,- b, and PPARg in proliferating and
involuting hemangiomas (data normalized to 18S rRNA and presented as relative to normal skin; *Po0.05 compared with normal skin,
wPo0.05 compared with proliferating
hemangioma;n¼3).(b)ImmunostainingofproliferatinghemangiomasforPDGFR-aandPDGFR-b(imagestakenat  20,insertsshowhighermagniﬁcation;brown¼DAB
staining, blue¼hematoxylin). (c) Immunoﬂuorescence double labeling for mesenchymal cell marker a-SMA and PDGFR-b (images taken at  20, green¼PDGFR-b,
red¼a-SMA)
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Cell Death and DiseaseSigniﬁcantly elevated levels of PDGF-B in hemangioma
stem cells. We next assessed whether hemangioma-
derived CD133þ stem cells express PDGF ligands and
receptors in culture. As both PDGFR-a and PDGFR-b are
expressed in proliferating hemangiomas (Figure 1), we
examined the expression of all ligands (PDGF-A, -B, -C,
and -D). Quantitative RT-PCR analysis of hemangioma-
derived stem cells (hemSCs) conﬁrmed the expression of
both PDGFRs. The transcript levels were not signiﬁcantly
different than the control bone marrow-mesenchymal pro-
genitor cells (bm-MPCs) (Figure 3a). When we assayed for
the PDGF ligands, we found signiﬁcantly elevated levels of
PDGF-B and downregulated expression of PDGF-A as
compared with the bm-MPCs (Figure 3b). There were no
signiﬁcant differences in the expression of PDGF-C and
PDGF-D. Using a sandwich immunoassay, we determined
the production of PDGF-BB in hemSC supernatant. Our
results show approximately 60pg of PDGF-BB in hemSCs
per ml media. PDGF-BB values in the bm-MPC media were
closer to the lower limit of the linear range, and showed
1.4pg/ml after overnight incubation (Figure 3c). The cell
lysates also showed signiﬁcantly higher PDGF-BB in
hemSCs compared with bm-MPCs (Figure 3d). Next, we
wanted to know whether PDGF-BB creates an autocrine loop
in the hemSCs. To achieve this, we probed the hemSCs for
activated PDGFRs under basal conditions (without exogen-
ous growth factor exposure). Using phospho-PDGFR a and b
immunoassays, we show that hemSCs exhibit constitutively
activated PDGFRs (Figure 3e). Furthermore, treatment of
hemSCs to exogenous 10ng/ml PDGF-BB further increased
the level of PDGFR-a and PDGFR-b tyrosine phosphoryla-
tion (Figure 3e). These ﬁndings suggest that the main ligand
for PDGFRs in hemangioma stem cells is PDGF-BB
(Figure 3f) and that an autocrine signaling loop exists.
PDGF does not alter hemSC proliferation. PDGF has
been shown to promote proliferation of mesenchymal cells
through inducing intracellular kinase activity.
11 We, therefore,
tested whether high levels of PDGF may regulate hemSC
mesenchymal/mesodermal phenotype and cell proliferation.
We elected to supplement hemSCs with exogenous PDGF-
BB for this experiment because, (1) hemSCs show elevated
levels of the PDGF-B chain (Figure 3b), (2) treatment of
hemSCs to exogenous PDGF-BB led to further increase in
PDGFR phosphorylation, thus providing us with a robust
system to assess for the PDGF-BB role, and (3) PDGF-BB
has been shown to be a mitogen for connective tissue cells
including smooth muscle cells and ﬁbroblasts.
12,13 Our
results show that exposure of the hemSCs to PDGF-BB did
not alter cell morphology or the expression of mesenchymal
markers, including a-SMA, calponin (a-SMA-associated
protein), or desmin (Figure 4a). Furthermore, PDGF-BB
exhibited no signiﬁcant effect on hemSC migration and
proliferation (Figures 4b and c).
PDGF-BB inhibits adipogenesis in hemangioma-derived
SCs in a dose-dependent manner. We investigated the
role of PDGF on the ﬁnal fate of the hemSCs: terminal
differentiation into adipocytes. We have previously shown
that these CD133þ hemSCs produce human adipocytes in
the mouse model of hemangioma, illustrating that these cells
are critical for the process of involution.
14 These human
adipocytes appear spontaneously in the mouse model
around 56 days following cell administration (time coinciding
with decreased microvessel density). To test the effect of
PDGF on adipogenesis, we exposed hemSCs to adipogenic
media supplemented with PDGF-AA, PDGF-AB, and PDGF-
BB. Of all three dimers tested, only PDGF-BB inhibited lipid
accumulation and adipogenic differentiation in the hemSCs
Figure 2 Phosphorylated PDGF receptors in proliferating hemangiomas. Immunostaining of proliferating hemangioma specimens for phospho-PDGFR-b (a) and
phospho-PDGFR-a (b) (images taken at  20, green¼PDGFR, blue¼DAPI)
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Cell Death and Disease(Figure 5a). This inhibition was associated with a marked
reduction in the expression of adipogenesis-speciﬁc tran-
scription factors, C/EBPa and PPARg
15–17 (Figure 5b). These
ﬁndings demonstrate that PDGF signaling actively inhibits
the induction of adipogenic transcription factors. We also
examined whether exposure to the adipogenic media itself
changes PDGFR expression in the hemSCs. Although a
slight decrease in PDGFR-b was seen in the hemSCs
exposed to the adipogenic media, it did not reach statistical
signiﬁcance (Figure 5c).
Next, we determined whether other growth factors that
regulate cell differentiation also inhibit adipogenesis in the
hemSCs. We tested the effect of vascular endothelial growth
factor (VEGF)-A and VEGF-B (involved in hemangioma
endothelial cell differentiation
18–20), stem cell factor (SCF)
and stromal-derived factor (SDF) (involved in mesenchymal
progenitor growth
21) on hemSC adipogenic differentiation. Oil
red O staining revealed that only PDGF-BB inhibited
adipogenesis in the hemSCs (Figure 5d). The effect of PDGF
was also dose dependent, as increasing the concen-
tration from 10 to 50ng/ml completely abolished
C/EBPa and PPARg expression and downregulated fatty-
acid-binding protein-4 (FABP-4) (Figures 6a and b). In
contrast, PDGF-AA, which does not bind to the PDGFR-b,
had no effect FABP-4 expression even when administered at
50ng/ml (Figure 6c). We also examined whether a similar
effect of PDGF-BB is evident in the bm-MPCs that express
PDGFRs and all PDGF ligands. Analysis of early and late
markers of adipogenesis showed a similar pattern to that of
hemSCs, whereby PDGF-BB (50ng/ml) inhibited C/EBPa,
Figure 3 Expression of PDGF signaling axis in hemangioma-derived CD133þ cells. (a) Expression of PDGFRs in hemSCs and bm-MPCs (data normalized to 18 S
rRNA and presented as relative to bm-MPCs; two different hemSC preparations run in triplicates were averaged). (b) Expression of PDGF transcripts in hemSCs (data
presented as in (a); *Po0.05 compared with bm-MPCs; right panel shows the expression of PDGF-A, PDGF-C, and PDGF-D at a lower scale). (c) PDGF-BB levels in media
from cells cultured for 48h in EBM2/20%FBS (with growth factors) (*Po0.05 compared with bm-MPCs). (d) PDGF-BB levels in cell lysates determined by ELISA (*Po0.05
compared with bm-MPCs). (e) Levels of phosphorylated PDGFR-a and -b in hemSCs with or without exogenous PDGF-BB stimulation (cells were stimulated with 10ng/ml
PDGF-BB; *Po0.05 compared with unstimulated cells). (f) Schematic illustration of the hypothesized PDGF polypeptides and the corresponding receptors on hemangioma
stem cell surface
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Cell Death and DiseasePPARg, and FABP-4 (Figure 6d). Interestingly, PPARg and
FABP-4 were downregulated in the bm-MPCs but not
completely normalized, as is the case for C/EBPa. This
suggests that PDGF-BB may have a direct regulatory role on
C/EBPa and the regulation of PPARg is secondary.
Negation of PDGFR-b activity normalizes the inhibitory
effect of PDGF-BB in hemSCs. To conﬁrm whether
autogenous PDGF signaling is involved in preventing
hemSCs to differentiate into adipocytes, we treated the cells
with chemical inhibitors of PDGFR tyrosine kinase activity.
Two inhibitors, AG-370 and AG-1296,
22–25 were selected
based on the inhibition of PDGF signaling in cell culture
studies. The cells were treated with the inhibitors for the
duration of the adipogenic differentiation. Oil red O staining
showed modest increases in adipocyte differentiation when
hemSC were treated with PDGFR inhibitor AG-1296 but not
with AG-370 (Figure 7a). Quantitative RT-PCR showed
signiﬁcantly elevated C/EBPa and PPARg upon treatment
of hemSCs with AG-1296 (Figure 7b). This indicated that the
PDGFR tyrosine kinase activity is required for the inhibitory
effect of PDGF-BB on hemSC differentiation. To gain further
insight into the contribution of PDGFR-a and PDGFR-b in this
signaling pathway, we used speciﬁc neutralizing antibodies
26
targeting the two subunits. Our results show that only
PDGFR-b neutralization upregulated both C/EBPa and
PPARg in cells exposed to adipogenic media (Figures 7a
and b). No signiﬁcant changes were observed with PDGFR-a
neutralizing antibody. We extended this study and deter-
mined whether these inhibitors and neutralizing antibodies
will also normalize the inhibitory effect of exogenous PDGF-
BB. By quantitative analysis, cells cultured in the presence of
PDGF-BB plus PDGF inhibitors showed higher levels of
C/EBPa, PPARg, and FABP-4 than with PDGF-BB alone
(Figure 7c). As it is difﬁcult to maintain receptor blockade
using neutralizing antibodies in culture, we performed stable
short hairpin RNA (shRNA)-mediated knockdown of the
individual PDGFRs. PDGFR-a and PDGFR-b shRNA plas-
mid transfection produced signiﬁcant silencing of the
receptor mRNA for approximately 30 days (corresponding
to 6 subcultures) (Figures 8a and b). Contrary to what we
noticed with the neutralizing antibody, downregulation of
PDGFR-a reduced the inhibitory effect of exogenous PDGF-
BB (Figure 8c). Almost half of the inhibitory effect of PDGF-
BB was normalized with PDGFR-a knockdown only. This was
not associated with altered expression of PDGFR-b
(Figure 8a). Similarly, we performed knockdown of
PDGFR-b and assayed the cells for the reversal of the
Figure 4 Effect of PDGF-BBon hemSC phenotypeand cellular proliferation. (a) Fluorescenceimmunostaining for mesenchymal markers a-SMA,calponin anddesmin in
hemSCs. Umbilical artery SMCs were used as control for the mural markers. Effect of exogenous PDGF-BB on hemSC migration (b) and proliferation (c) (data presented as
relative to control media treated cells; n¼3)
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Cell Death and DiseasePDGF-BB effect. Suppression of PDGFR-b almost comple-
tely reversed the effect of PDGF-BB (Figure 8c) indicating
that receptor-b is the major receptor mediating the inhibitory
effect of PDGF-BB (Figure 8d).
Discussion
This study was based on the hypothesis that speciﬁc isoforms
of PDGF are involved in the involution phase of hemangioma,
and that the regulation of adipogenesis is via speciﬁc
receptor-mediated signaling mechanisms. Data from our
study demonstrates that PDGF signaling inhibits the differ-
entiation of the hemangioma stem cells into adipocytes.
Levels of adipogenic transcription factors (C/EBPa and
PPARg) and late marker of adipogenesis (FABP-4) are
increased following differentiation of both hemangioma
derived SCs and bm-MPCs. Addition of PDGF-BB speciﬁcally
prevented the activation of C/EBPa and PPARg and down-
regulatedFABP-4expression.Furthermore,weshowthatthis
inhibitory effect of PDGF-BB is mediated by PDGFR-b.
This is the ﬁrst study that has evaluated the role of PDGF
signaling in hemangioma SCs. There are, however, reports of
PDGFalteringadipogenicdifferentiationin‘pre-adipocyte’cell
lines. For example, PDGF-BB was shown to be essential in
inducing adipogenesis in serum-free culture of 3T3-L1 pre-
adipocytes.
27,28 This serum-free culture was devised to
decipher the role of critical culture components needed for
adipocytic differentiation. These studies have demonstrated
induction of C/EBPa by the addition of PDGF-BB in the
differentiation media. In the same cell line, PDGFR-b itself is
downregulated when the cells are treated with differentiation
media.
29 In human primary pre-adipocyte cultures (isolated
from sub-cutaneous biopsy specimens), PDGF-AA and
PDGF-BB were shown to be ineffective in inducing or
inhibiting PPARg and glycerol 3-phosphate dehydrogenase
(expressed by adipocytes
30).
31 However, both PDGF-AA and
PDGF-BB increased cell proliferation. These ﬁndings are in
contrast to what we see in the hemSCs and even bm-MPCs.
We show that PDGF-BB is not a mitogen for hemSCs and,
in adipogenic conditions, signiﬁcantly inhibits the induction of
C/EBPa and PPARg in both hemSCs and bm-MPCs.
The importance of PDGF signaling in the maintenance of
tumor growth is well established. The role of PDGF signaling
involves the recruitment of perivascular cells and stabilization of
the blood vessels.
9,10 In mice, inhibition of PDGFR-b con-
tributed to reduced tumor growth.
32 In a separate study,
administering a PDGFR inhibitor stripped mouse tumor
endothelial cells of pericytes, thus rendering the tumors more
susceptible to chemotherapy.
33 PDGF-BB has also been
shown to promote endothelial proliferation.
34 This may suggest
a unique dual role of PDGF signaling in hemangioma
pathogenesis. High PDGF levels during the proliferative phase
may cause endothelial cells to proliferate while inhibiting the
differentiation of adipocytes. We have noted almost a 200-fold
increased expression of PDGF-B in hemSCs as compared with
the bm-MPCs. This may be due to the primitive state of the
hemSCs. Our previous studies show that hemSCs and bm-
MPCs share many cell adhesion molecules. The cells are also
similar in a number of functional assays except for endothelial
and neuroglial differentiation, which is only evident in the
Figure 5 PDGF-BB inhibits adipogenic differentiation in hemSCs. (a) Representative oil red O staining of hemSCs cultured in adipogenic differentiation media
supplementedwith10ng/mlof PDGF-AA,-AB,or-BB.(b)QuantitativeanalysisofadipogenicdifferentiationinthepresenceofPDGFpolypeptideswasassessedbyreal-time
RT-PCR for adipogenesis-speciﬁc transcription factors, C/EBPa and PPARg (data normalized to 18S rRNA and presented as relative to adipogenic media; *Po0.05
comparedwith theadipogenicmedia;n¼3).(c)Effectof adipogenicdifferentiationon PDGFRexpressioninhemSCsat day7.(d)OilredOstainingof hemSCsculturedwith
different growth factors (each at 10ng/ml) illustrating speciﬁc inhibition of hemSC adipogenesis by PDGF signaling
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Cell Death and DiseasehemSCs. These ﬁndings show that hemSCs are uncommitted
SCs, whereas bm-MPC (when cultured under identical condi-
tions) are limited to the mesenchymal lineage. This enhanced
differentiation state of the bm-MPCs is possibly associated with
reduced PDGF-B expression.
Elevated PDGF levels in the hemangioma tissue may also
be an indirect phenomenon. As all tumors change cellular
compositionatdifferentstagesofgrowth,itispossiblethatthe
changing cellular composition in hemangioma during the
involutive phase indirectly leads to reduced PDGF-B content
and triggers adipocyte differentiation. We know that the
involutive phase is characterized by disappearance of blood
vessels, coinciding with the appearance of adipocytes. An
exact phenocopy of this is found in our mouse model.
14
Endothelial cellshavebeen shownto expressPDGF-B, which
is involved in mural cell recruitment and vessel stabilization.
A decrease in the vascular endothelial cells may, therefore,
lead to reduced PDGF-B levels in hemangioma tumors.
Our study represents the ﬁrst step toward understanding
the role of PDGF signaling on the natural history of infantile
hemangioma.Theﬁndingsmayhavethepotentialtoprovidea
novel therapeutic target in PDGF signaling, not just for
hemangioma but also other conditions, such as obesity and
diabetes. Overall, our data point to an inhibitory role for
receptor-mediated PDGF signaling in hemangioma involu-
tion. Further studies are needed to determine the exact
mechanisms underlying altered PDGF-B expression in the
hemangiomaSCs.PDGFcouldturnouttobethefundamental
intrinsic mechanism of adipocyte development.
Materials and Methods
Hemangioma tissues and cells. Parafﬁn-embedded hemangioma speci-
mens were obtained from the Department of Pathology Archives at the London
Health Sciences Center (LHSC). The proliferating phase of hemangiomas was
conﬁrmed by histological analysis. Proliferating hemangioma-derived CD133þ
cells (hemSCs) were kindly provided by Dr Joyce Bischoff (Children’s Hospital
Boston, Boston, MA, USA). We have previously characterized these hemangioma-
derived CD133þ cells by ﬂow cytometry, immunostaining, quantitative RT-
PCR, and functional tests including multilineage differentiation.
14 Bone marrow-
mesenchymal progenitor cells (bm-MPCs; isolated from fresh bone marrow
preparations; Lonza Inc., Walkersville, MD, USA) were used as controls. We used
bm-MPCs as we have shown adipogenic differentiation in the bm-MPCs under
identical conditions (differentiation media and the time point) as the hemSCs.
14 All
studies were conducted following approval by the Research Ethics Board at The
University of Western Ontario (London, Ontario, Canada).
hemSCs were cultured on ﬁbronectin-coated (1mg/cm
2, FC010-10, Millipore,
Temecula, CA, USA) plates in Endothelial Basal Media-2 (EBM2; Lonza Inc.)
supplemented with 20% FBS (Lonza Inc.) and EGM-2 SingleQuots (CC-4176,
Lonza Inc.) and 1X antibiotic antimycoticmedia (PSF; Invitrogen, Grand Island, NY,
USA). All cells were cultured under identical conditions and the experiments were
Figure 6 PDGF-BB, but no other PDGF polypeptides, prevent full functional differentiation of hemSCs. (a) Oil red O staining of hemSCs cultured in low (10ng/ml) and
high (50ng/ml) PDGF polypeptide levels. PDGF-AA and –AB were ineffective against preventing adipogenic differentiation at 10 and 50ng/ml. (b) Quantitative analysis of
early adipogenesis-speciﬁc transcription factors (C/EBPa and PPARg) and late marker of adipocytes, FABP-4 (*Po0.05 compared to adipogenic media; n¼3).
(c) Expression of FABP-4 in hemSCs treated with 50ng/ml PDGF-AA. (d) Inhibition of adipogenesis by PDGF-BB in bm-MPCs (data presented relative to adipogenic media;
*Po0.05 compared with adipogenic media; n¼3)
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Cell Death and DiseaseFigure 7 Inhibiting cell-autogenous PDGF signaling enhances adipogenesis. (a) Oil red O staining of hemSCs exposed to adipogenic media with or without PDGFR
inhibitors, AG-370 and AG-1296, and PDGFR neutralizing antibodies. (b) Quantitative analysis of C/EBPa and PPARg in cells exposed to PDGF inhibitors as in (a) (data
presented relative to control media; *Po0.05 compared with control media;
wPo0.05 compared with adipogenic media; n¼3). (c) Effect of PDGFR-a and PDGFR-b-
neutralizing antibodies and chemical inhibitors on reversing the inhibition by exogenous PDGF-BB (*Po0.05 compared with PDGF-BB treatment)
Figure 8 PDGF-BB employs PDGFR-b in hemSCs. shRNA-mediated knockdown of PDGFR-a (a) and PDGFR-b (b) in hemSCs at sub-passage 1 (subP1; following 2
weeks of puromycin selection) and sub-passage 6 (six serial passages after puromycin selection) (*Po0.05 compared with control shRNA). (c) shRNA-knockdown of
PDGFR-a and PDGFR-b in hemSCs reduced the inhibitory effect of PDGF-BB on hemSC adipogenesis (*Po0.05 compared with control shRNA). (d) Schematic illustrating
the ﬁndings of the study and our working hypothesis. High levels of PDGF-BB from hemSCs during proliferation mediate intracellular signaling through PDGFR-b
(predominantly PDGFR-bb homodimer with contribution from PDGFR-ab heterodimer) to inhibit C/EBPa and PPARg expression and adipogenesis (i.e., involution). Upon
regression of the vessels and removal of the PDGF-BB source, adipogenesis is triggered
PDGF in hemangioma regression
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Cell Death and Diseaseperformed with a minimum of three biological replicates (cell preparations from
different hemangioma specimens) and three technical replicates.
Immunostaining. Tissue sections were deparafﬁnized in xylene and
hydrated. Antigen retrieval was then carried out in Tris/EDTA buffer (10mM
Trizma-base, 1mM EDTA, 0.05% Tween-20, pH 9.0) for 15min at 1211C using
2100 Retriever (Electron Microscopy Sciences, Hatﬁeld, PA, USA). Sections were
then blocked in 5% horse serum (Vector Laboratories, Burlington, Ontario,
Canada) for 30min and incubated with one of the following antibodies: mouse
anti-PDGFR-a (1:200; R & D Systems, Minneapolis, MN, USA), mouse anti-
PDGFR-b (1:50; R & D Systems), mouse anti-a-SMA (1:500; Sigma-Aldrich,
Oakville, Ontario, Canada), and mouse anti-CD31 (1:50; Dako, Mississauga,
Ontario, Canada). Endogenous peroxidase was quenched with 3% hydrogen
peroxide. Secondary peroxidase-conjugated horse anti-mouse IgG (1:200; Vector
Laboratories) was used with ImmPACT DAB (3,30-diaminobenzidine; Vector
Laboratories) for detection. Slides were counterstained in hematoxylin (Sigma-
Aldrich) and mounted in Clarion Mounting Medium (Sigma-Aldrich). For
ﬂuorescent double-labeling, slides were sequentially stained for two antigens
using goat anti-PDGFR-b antibody (1:100; Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and mouse anti-a-SMA antibody. FITC and texas red-conjugated
secondary antibodies (Vector Laboratories) were used for detection. Slides were
counterstained with DAPI (Vector Laboratories). Hemangioma sections were also
stained for phospho-PDGFRs (phospho-PDGFR-b (Y1021) and phospho-PDGFR-
a (Y742), Abcam, Cambridge, MA, USA) using the same protocol. For cell
staining, we also used the mouse anti-calponin (Dako) and rabbit anti-desmin
(Abcam). Images were taken using the Olympus BX-51 microscope (Olympus
Canada Inc., Richmond Hill, Ontario, Canada) equipped with a Spot PursuitTM
digital camera (SPOT Imaging Solutions, Sterling Heights, MI, USA).
Quantitative real time RT-PCR. Total RNA was isolated from the parafﬁn-
embedded hemangioma sections by using High Pure FFPE RNA Micro Kit (Roche
Diagnostics Canada, Laval, Quebec, Canada). A similar protocol was employed to
isolate RNA from human fetal skin sections (Abcam). For cultured cells, we used
RNeasy Mini Plus and Micro Plus Kits (QIAGEN, Mississauga, Ontario, Canada).
The purity of the samples was determined by 260:280nm absorbance
measurements (Quent Spectrophotometer, Pharmacia Biotech, Baie d’Urfe,
Quebec, Canada). The quantity was determined by Qubit Broad Range RNA
assay in the Qubit Fluorometer (Invitrogen). cDNA synthesis was performed with
iScript cDNA Synthesis Kit (170-8891; Bio-Rad Laboratories, Hercules, CA, USA).
Primers used for RT-PCR were obtained from Qiagen except for PPARg2, which
was obtained from Life Technologies (Burlington, Ontario, Canada): (PDGF-A,
QT01664488; PDGF-B, QT00001260; PDGF-C, QT00026551; PDGF-D,
QT01667253; PDGFR-a, QT00012719; PDGFR-b, QT00082327; C/EBPa,
QT00203357; FABP4, QT01667694; PPARg2, ATTGACCCAGAAAGCGATTCC
and CAAAGGAGTGGGAGTGGTCT; and 18S rRNA, QT00199367). The RT-PCR
reactions consisted of 10ml 2X SYBR Advantage qPCR premix (Clontech
Laboratories, Inc., Mountain View, CA, USA), 2ml primers (10mM concentration),
2ml cDNA, and 6ml of water. 18S rRNA was used as the housekeeping gene.
Data was analyzed by the standard curve method and presented as percent
control treatment or control cells.
PDGF-BB measurements and PDGFR tyrosine phosphorylation.
hemSCs and bm-MPCs were cultured on FN-coated plates in EBM2 media
supplemented with 20% FBS (without SingleQuots or other growth factors). Forty
eight hours later, the cell media was collected and PDGF-BB content was
measured by Human PDGF-BB Quantikine ELISA (R & D Systems). This
immunoassay is speciﬁc for human PDGF-BB and free from interference from
bovine PDGF-BB. The PDGF-BB standards were used to determine the
concentration of PDGF-BB in cell supernatants. Media from bm-MPCs was
incubated overnight and hemSC media was incubated for 2h. Cell lysates were
also prepared to measure PDGF-BB levels using the same ELISA. The lysates
were also used to measure tyrosine phosphorylated PDGF receptors a (PathScan
Phospho-PDGF Receptor a (Tyr849) Sandwich ELISA Kit; Cell Signaling
Technology, Pickering, Ontario, Canada) and b (PathScan Phospho-PDGF
Receptor b (Tyr751) Sandwich ELISA Kit; Cell Signaling Technology). Phospho-
PDGF receptor levels were presented as OD450.
PDGF adipogenesis assays. hemSCs cells were cultured in DMEM media
(Invitrogen) supplemented with 10% FBS (control media) or StemPro
Adipogenesis Differentiation media (Invitrogen) for 7 days. Media was changed
every other day. After 7 days of induction, the cells were either stained with Oil
Red O or used for RNA isolation and quantiﬁcation of adipogenesis. These genes
included two transcription factors necessary for adipogenic differentiation (C/EBPa
and PPARg).
16,17 We also examined fatty acid binding protein-4 (FABP-4),
15 which
is a late adipogenesis marker. The expression of FABP-4 is developmentally
regulated by fatty acids and is expressed by mature adipocytes.
16,17
To study the effect of PDGF on hemSC adipogenic differentiation, we included
10ng/ml PDGF-AA, PDGF-AB, PDGF-BB, SCF, SDF-1, or VEGF-A and -B in the
adipogenic differentiationmedia(all growth factors were obtained from R & DSystems:
221-AA-010, 20-BB-010, 222-AB-010, 255-SC-010, 350-NS-010, 293-VE-010, and
751-VE-025). The media was changed every other day and the cells were exposed to
the growth factors for the duration of the 7-day differentiation experiment. Some cells
were treated with higher concentrations of the growth factors (concentration shown in
the ﬁgure legend). PDGF receptor signaling was inhibited by three different means.
(1) Cells were pretreated for 30min with inhibitors of PDGFR tyrosine kinase activity,
AG-370 and AG-1296.
22–25 AG-370 was used at 20mM and AG-1296 at 5mM
(Cayman Chemicals, Ann Arbor, MI, USA; 10010592-1 and 10010568-1). The cells
were then induced to differentiate in adipogenesis media with or without PDGF-BB. In
addition to the pre-treatment, the cells were continuously exposed to the inhibitors
through media changes. The concentration of these inhibitors was according to
previous studies in human cells.
22,35,36 ( 2 )W ea l s ob l o c k e dt h eP D G F Rs i g n a l i n gb y
using PDGFR-a (MAB322; R & D Systems) and PDGFR-b (AF385, R & D Systems)
neutralizing antibodies (both at 2mg/ml). Similar to the chemical inhibitors, the antibody
treatment comprised a 30-min pre-treatment and exposure throughout the 7-day
experiment. These antibodies have also been documented to inhibit PDGFR activation
in human cells.
26 And lastly, we stably knocked down the expression of PDGFR-a and
PDGFR-b in the hemSCs (described below).
shRNA plasmid transfections. Cells were plated on FN-coated multi-well
plates at a density of 40000cells/cm
2 in complete EBM2 media. The media
was changed to antibiotic/antimycotic-free media 24h before the transfections.
The cells were transfected with control shRNA (sc-108060; Santa Cruz
Biotechnology), PDGFR-a shRNA (sc-29443-SH; Santa Cruz Biotechnology)
plasmid DNA, or PDGFR-b shRNA (sc-29442-SH; Santa Cruz Biotechnology) at a
concentration of 0.25mg/cm
2 surface area. Plasmid DNA was administered using
lipofectamine (Invitrogen). Cells were incubated for 7h and then supplemented
with 1ml of normal growth media (containing PSF). Transfected cells were puriﬁed
by puromycin treatment for 2 weeks. The knockdown efﬁciency was determined
after puromycin selection and following 6 serial passages by real time RT-PCR.
Oil Red O Staining. Oil-Red-O staining was performed to determine
adipogenic differentiation qualitatively. Cells were ﬁxed in 10% neutral-buffered
formalin for 5min and then dehydrated with propylene. The plates were incubated
8min at 601C with a 0.5% Oil red O stain (Sigma-Aldrich). Following a wash,
hematoxylin counterstaining was performed and images were taken using Meiji
TC5400 inverted microscope (Meiji Techno American, Santa Clara, CA, USA)
equipped with Spot Idea digital camera (SPOT Imaging Solutions).
Cell proliferation and migration. To measure the effect of PDGF-BB on
hemSC proliferation, we plated the cells on FN-coated multi-well plates at a density of
2500cells/cm
2. After 24h in control media, the media was removed and cells were
treated with either EBM2/1% FBS (control) or EBM2/1% FBS with 10ng/ml PDGF-BB.
The number of viable cells was determined after 48h using the tetrazolium salt
reagent (WST-1, Clontech) and measuring absorbance at 450nm in a Multiskan FC
Microplate Photometer (Thermo Scientiﬁc, Nepean, Ontario, Canada).
Cell migration assay was performed on FN-coated (100mg/cm
2) 6.5-mm Transwells
with 8.0mm pore polycarbonate membrane inserts (BD Falcon Cell Culture inserts; BD
Biosciences, Mississauga, Ontario, Canada). hemSCs were suspended in control
media (EBM2/1% FBS) and plated onto the inserts in triplicates, and at a density of
10000 cells/insert. The lower chamber contained with control media or media
supplemented with 10ng/ml PDGF-BB. After 24h, the migrated cells were stained with
DAPI. Images were taken at  20 magniﬁcation using Olympus BX-51 and cell
migration was computed using Image J software (http://rsbweb.nih.gov/ij/).
Statistical analysis. The data are expressed as means±S.E.M. Analysis of
variance followed by two-tailed Student’s unpaired t-tests were performed to
determine the signiﬁcance level. P values o0.05 were considered statistically
signiﬁcant.
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